These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 36710501

  • 1. The development of BVDU: An odyssey.
    De Clercq E.
    Antivir Chem Chemother; 2023; 31():20402066231152971. PubMed ID: 36710501
    [Abstract] [Full Text] [Related]

  • 2. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
    De Clercq E.
    Biochem Pharmacol; 2004 Dec 15; 68(12):2301-15. PubMed ID: 15548377
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase.
    Sienaert R, Naesens L, Brancale A, De Clercq E, McGuigan C, Balzarini J.
    Mol Pharmacol; 2002 Feb 15; 61(2):249-54. PubMed ID: 11809847
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication.
    Balzarini J, McGuigan C.
    J Antimicrob Chemother; 2002 Jul 15; 50(1):5-9. PubMed ID: 12096000
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides.
    Balzarini J, McGuigan C.
    Biochim Biophys Acta; 2002 Jul 18; 1587(2-3):287-95. PubMed ID: 12084470
    [Abstract] [Full Text] [Related]

  • 8. FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
    De Clercq E.
    Viruses; 2022 Apr 07; 14(4):. PubMed ID: 35458500
    [Abstract] [Full Text] [Related]

  • 9. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
    Yokota T, Konno K, Shigeta S, De Clercq E.
    Mol Pharmacol; 1984 Sep 07; 26(2):376-80. PubMed ID: 6090888
    [Abstract] [Full Text] [Related]

  • 10. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
    De Clercq E, Descamps J, Ogata M, Shigeta S.
    Antimicrob Agents Chemother; 1982 Jan 07; 21(1):33-8. PubMed ID: 6282207
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
    Grignet-Debrus C, Cool V, Baudson N, Degrève B, Balzarini J, De Leval L, Debrus S, Velu T, Calberg-Bacq CM.
    Cancer Gene Ther; 2000 Feb 07; 7(2):215-23. PubMed ID: 10770629
    [Abstract] [Full Text] [Related]

  • 12. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C.
    Mol Pharmacol; 2002 May 07; 61(5):1140-5. PubMed ID: 11961132
    [Abstract] [Full Text] [Related]

  • 13. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
    Balzarini J, De Clercq E, Verbruggen A, Ayusawa D, Shimizu K, Seno T.
    Mol Pharmacol; 1987 Sep 07; 32(3):410-6. PubMed ID: 2823092
    [Abstract] [Full Text] [Related]

  • 14. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.
    Balzarini J, De Clercq E, Baumgartner H, Bodenteich M, Griengl H.
    Mol Pharmacol; 1990 Mar 07; 37(3):395-401. PubMed ID: 2156153
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Wilber BA, Docherty JJ.
    J Gen Virol; 1994 Jul 07; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
    [Abstract] [Full Text] [Related]

  • 18. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
    Mercier-Darty M, Boutolleau D, Lepeule R, Rodriguez C, Burrel S.
    Antiviral Res; 2018 Mar 07; 151():20-23. PubMed ID: 29337163
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.